Echarki Zerif

Echarki Zerif

Auto-generated profile, based on publicly available information

Echarki Zerif

Research Center on Aging, Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
MAMehdi ALAMI
Mehdi ALAMI
EZEcharki Zerif
Echarki Zerif
Abdelouahed KhalilAbdelouahed Khalil
Abdelouahed Khalil
NHNabil Hajji
Nabil Hajji
CRCharles Ramassamy
Charles Ramassamy
HBHicham Berrougui
Hicham Berrougui
Background: Alzheimer's disease (AD) is a chronic brain degenerative disease that leads to dementia. Objective: The aim of the present study is to investigate the neuroprotective impact of sodium-glucose cotransporter-2 inhibitors (SGLT2i) (empagliflozin and dapagliflozin) on tau phosphorylation, oxidative stress, and neuroinflammation. Methods: We used MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) assay, annexin-V-FITC kit, and DCFH-DA (dichloro-dihydro-fluorescein diacetate) to respectively evaluate the effect of the SGLT2i (empagliflozin and dapagliflozin) on amyloid-β (Aβ) 1–42 -induced neuronal death, apoptosis, and oxidative stress. The expression of NLRP3-inflammasome, phospho-Tau181, glycogen synthase kinase-3 beta (GSK-3β), cyclin-dependent kinase 5 (CdK5), and histone deacetylase 6 (HDAC6), was quantified by flow cytometry. Drug distribution in the mice's brains was assessed by liquid chromatography-mass spectrometry (LC-MS). Results: Aβ 1–42 significantly reduced cell viability and increased apoptosis, which was reversed by using gliflozins. SGLT2i significantly reduced Aβ 1–42 -induced reactive oxygen species generation, downregulated NLRP3-inflammasome, and diminished tau pathology. Mechanistically, the last effect involved the modulation of GSK-3β and CdK5 protein expression. However, the tested treatments did not modify the Aβ 1–42 -stimulating effect of HDAC6. Gliflozins are substrates of drug transporters ATP-binding cassette sub-family B member 1 and/or ATP binding cassette subfamily G member 2 (ABCB1 and ABCG2), and Elacridar significantly enhances their brain distribution. Conclusions: SGLT2i empagliflozin and dapagliflozin exhibited neuroprotective actions against human Aβ 1–42 -induced neurotoxicity.

30 April 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MAMehdi Alami
Mehdi Alami
FAFatima Zahra El Allouch
Fatima Zahra El Allouch
HBHicham Berrougui
Hicham Berrougui
EZEcharki Zerif
Echarki Zerif
JOJamal Oubaouz
Jamal Oubaouz
Abdelouahed KhalilAbdelouahed Khalil
Abdelouahed Khalil
BackgroundATP-Binding cassette (ABC) transporters such as P-glycoprotein (P-gp)/ABCB1 actively efflux xenobiotics, including therapeutic agents, leading to drug resistance. While elacridar is a well-established P-gp inhibitor in peripheral tissues, its effects on the central nervous system, particularly on neuroglioma P-gp, remain incompletely understood.PurposeWe aimed to evaluate the time-dependent inhibition of P-gp by elacridar in the H4 neuroglioma cells.MethodsP-gp activity was studied by measuring the intracellular accumulation of rhodamine 123 (Rho123) using flow cytometry. We conducted in-silico analyses to explore the biological interactions between elacridar and the P-gp transporters.ResultsElacridar exhibited a biphasic, time-dependent modulation of P-gp activity. At early time points (1/2h and 1h), elacridar unexpectedly decreased the intracellular concentration of Rho123. This effect was reversed at 4h, when elacridar significantly increased Rho123 accumulation (p<0.05). However, this inhibitory effect progressively declined at 12h and was strongly abolished by 24 h.ConclusionOverall, these results are in favour of a dual, time-dependent modulation of elacridar on neuroglioma P-gp activity. Our findings provided the first functional evidence of P-gp-mediated efflux in neuroglioma cells, highlighting its potential role in regulating drug disposition in the central nervous system. This may have important implications for the treatment of neurodegenerative diseases.